Solid Biosciences hit hard by study stoppage

Duchenne’s muscular dystrophy (DMD) specialist Solid Biosciences (Nasdaq: SLDB) has been told by the US  Food and Drug Administration it must pause its Phase I/II IGNITE DMD study of SGT-001 microdystrophin gene transfer.

The decision, which wiped 60% off the firm’s share price, was down to an adverse reaction from the first patient to be dosed.

The patient, who has since recovered, was hospitalized due to laboratory findings that included “a decrease in platelet count followed by a reduction in red blood cell count and evidence of complement activation.”